Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus rituximab vs physician’s choice in relapsed or refractory mantle cell lymphoma
2023-503618-64-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of ibrutinib in mantle cell lymphoma (MCL) (3 arms), sponsored by Janssen Pharmaceutical. Started Nov 2023; status: completed.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2023-503618-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503618-64-00.